Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardiopulmonary Disease

被引：3

作者：

Hussein, Ayman A. ^{[1
]}

Alvarez, Paulino ^{[2
]}

Reed, Grant ^{[3
]}

Heresi, Gustavo A. ^{[4
]}

机构：

[1] Cleveland Clin, Dept Cardiovasc Med, Sect Cardiac Pacing & Electrophysiol, Cleveland, OH 44106 USA

[2] Cleveland Clin, Sect Heart Failure, Dept Cardiovasc Med, Cleveland, OH 44106 USA

[3] Cleveland Clin, Sect Intervent Cardiol, Dept Cardiovasc Med, Cleveland, OH 44106 USA

[4] Cleveland Clin, Dept Pulm & Crit Care Med, Cleveland, OH 44106 USA

来源：

CHEST | 2022年 / 161卷 / 05期

关键词：

direct oral anticoagulant; off-label use; thromboembolism; VALVULAR HEART-DISEASE; ATRIAL-FIBRILLATION; PULMONARY-HYPERTENSION; SINUS RHYTHM; ANTITHROMBOTIC THERAPY; VALVE THROMBOSIS; WARFARIN; FAILURE; OUTCOMES; STROKE;

D O I：

10.1016/j.chest.2022.01.033

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Direct oral anticoagulants (DOACs) are increasingly used in clinical practice and have become essential in the management of atrial fibrillation and VTE. The enthusiasm for DOACs has fueled the off-label application of these agents in cardiopulmonary disease, and their use has often outpaced the evidence supporting their application. This article reviews the evidence and current off-label use of DOACs in various cardiopulmonary disease states.

引用

页码：1360 / 1369

页数：10

共 50 条

[21] Off-Label Use of New Oral Anticoagulants A One-Way Ticket to Nowhere
Molina, Carlos A.
Selim, Magdy H.
[J]. STROKE, 2014, 45 (07) : 2158 - 2159
[22] Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply
Alcalai, Ronny
Elbaz-Greener, Gabby
Leibowitz, David
[J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (01) : E3 - E3
[23] Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
Alexandros Briasoulis
Yubo Gao
Chakradhari Inampudi
Paulino Alvarez
Rabea Asleh
Elizabeth Chrischilles
Enrique C. Leira
Mary Vaughan-Sarrazin
[J]. BMC Cardiovascular Disorders, 20
[24] Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
Briasoulis, Alexandros
Gao, Yubo
Inampudi, Chakradhari
Alvarez, Paulino
Asleh, Rabea
Chrischilles, Elizabeth
Leira, Enrique C.
Vaughan-Sarrazin, Mary
[J]. BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01)
[25] Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation
Arbel, Ronen
Sergienko, Ruslan
Hammerman, Ariel
Greenberg-Dotan, Sari
Batat, Erez
Avnery, Orly
Ellis, Martin H.
[J]. AMERICAN JOURNAL OF MEDICINE, 2019, 132 (07): : 847 - +
[26] Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism
John A. Saunders
Whitney L. Gustafson
Sara R. Vazquez
Aubrey E. Jones
Daniel M. Witt
[J]. Journal of Thrombosis and Thrombolysis, 2019, 48 : 506 - 510
[27] Real-world assessment of off-label direct oral anticoagulant dosing for venous thromboembolism
Saunders, John A.
Gustafson, Whitney L.
Vazquez, Sara R.
Jones, Aubrey E.
Witt, Daniel M.
[J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 48 (03) : 506 - 510
[28] Oral medicine: Off-label cream use
S. Porter
V. Mercadante
S. Fedele
[J]. British Dental Journal, 2014, 217 : 660 - 661
[29] ORAL MEDICINE Off-label cream use
Porter, S.
Mercadante, V.
Fedele, S.
[J]. BRITISH DENTAL JOURNAL, 2014, 217 (12) : 660 - 661
[30] Off-label use of biologicals in the management of inflammatory oral mucosal disease
O'Neill, Iain David
[J]. JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2008, 37 (10) : 575 - 581

← 1 2 3 4 5 →